natgillin/translations-raw huggingface dataset:
The object of the present invention is to provide a discharge device that allows a metered dose of liquid to be discharged in more than one step or action, in particular, wherein the discharge can be interrupted and continued. 
Cilj predloženog izuma je osigurati napravu za pražnjenje koja omogućuje pražnjenje jedne odmjerene doze tekućine u više koraka ili djelovanja, pri čemu se, posebno, pražnjenje može prekinuti i nastaviti.
The method according to claim 1, wherein the hollow bodies (11) are constructed as microorganism-culture hollow bodies (11), having their hollow interior spaces set with microbial strains (114) 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su šuplja tijela (11) konstruirana kao šuplja tijela s kulturom mikroorganizama (11), čiji šuplji unutarnji prostori sadrže sojeve mikroorganizama (114).
In another embodiment of the invention: 
Datum podnošenja europske prijave patenta:
selecting said candidate compound if it inhibits the activity/expression/function of Dynamin 2. 
odabir navedenog spoja kandidat ako isti pokazuje aktivnost/eksprimiranje/funkciju dinamina 2.
Netupitant for use according to claims 1-3, wherein a therapeutically effective amount of a 5-HT3 antagonist is further administered. 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-2, pri čemu se dalje primjenjuje terapijski učinkovita količina 5-HT3 antagonista.
The method of claim 7, wherein the antigen binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a scFv, a Fv, and a diabody. 
Postupak prema patentnom zahtjevu 7, naznačen time, da je fragment za vezanje antigena odabran iz skupine koja se sastoji od fragmenta Fab, fragmenta Fab', fragmenta F(ab')2, scFv, Fv i dimernog fragmenta protutijela scFv ili Fv.
XII are described in U.S. Pat. 
US (73) Nositelj patenta:
An agent for oral administration for use in the treatment of fructose intolerance, the agent comprising: 
PATENTNI ZAHTJEVI Sredstvo za oralnu primjenu nanijenjeno liječenju netolerancije fruktoza, sredstvo koje sadrži:
The method of claim 10, wherein the porphyria is a hepatic porphyria selected from the group consisting of acute intermittent porphyria (AIP) hereditary coproporphyria (HCP), variegate porphyria (VP), ALA deyhdratase deficiency porphyria (ADP), and hepatoerythropoietic porphyria. 
porfirija je jetrena porfirija koja se bira iz skupa koji čine akutna intermitentna porfirija (AIP), nasljedna koproporfirija (HCP), porfirija variegata (VP), Porfirija zbog manjka ALAD (ADP), i hepatoeritropoetska porfirija;
The modified sulfamidase or the sulfamidase composition according to claim 15, for use in treatment of a mammal afflicted with a lysosomal storage disease, in particular mucopolysaccharidosis IIIA (MPS IIIA). 
Modificirana sulfamidaza ili supstanca sulfamidaze sukladno patentnom zahtjevu 15, radi liječenja sisavaca s bolesti lizozomnog skladištenja, specifično mukopolisaharidoza INA (MPS IIIA).
mL 16 Dilution with fresh medium 
Razrjeđenje svježim medijem 3 x 850 cm!
in a moulding process. 
postupkom prešanja.
A ruminant compound feed, characterized in that in addition to conventional feed raw materials, which include protein, carbohydrate and fat containing materials, the feed contains inside and on the surface of feed raw material particles a fatty acid mixture wherein the content of free palmitic acid is at least 90 % and the total amount of the fatty acid mixture in said ruminant feed is higher than 10 % by weight. 
Postupak pripreme životinjske hrane, naznačeno time da se među konvencionalne sastojke životinjske hrane i konvencionalne aditive životinjske hrane te pomoćna sredstva dodaje, miješanjem, mješavina masnih kiselina u kojoj je udio zasićenih masnih kiselina veći od 90% i iznos mješavine masnih kiselina u životnjskoj hrani od 1 do 10% težine, te naznačeno time da mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
To a 2L round bottom flask containing a magnetic stirred suspension of commercial 5-bromo-2-chlorobenzoic acid (410g, 1.74 mol) in 700 mL of CH2Cl2 was added oxalyl chloride (235g, 1.85 mol) followed by 1.5 mL of DMF. 
U posudu sa okruglim dnom od 2 litre koja sadrži magnetno miješanu suspenziju komercijalno 5-bromo-2-klorobenzoeve kiseline (410 g, 1.74 mol) u 700 mL CH2Cl2 dodan je oksalil klorid (235 g, 1.85 mol) 1 zatim 1.5 mL DMEF.
Preferably, the polyphenols and/or proteins are desorbed from the PVPP particles by increasing the pH to at least 10.0, more preferably to at least 11.0. 
Postupak prema bilo kojem od prethodnih Zahtjeva, gdje se polifenoli i/ili polifenoli desorbiraju s PVPP čestica povećanjem pH vrijednosti do najmanje 10,0, a poželjno do najmanje 11,0.
Cocoa-derived material according to any of claims 1 to 7, wherein said cocoa extract comprises between 5 and 15 % by weight of the extract of polyphenol monomers whereby said monomers comprise between 5 and 15% by weight of the extract of epicatechin and between 0.5 and 5 % by weight of the extract of catechin. 
Tvar dobivena iz kakaa u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time, da dotični ekstrakt kakaa sadrži maseni udjel polifenol monomera u rasponu od 5 do 15 % mase ekstrakta pri čemu dotični monomeri sadrže maseni udjel epikatekina u rasponu od 5 do 15 % mase ekstrakta te maseni udjel katekina u rasponu od 0,5 do 5 % mase ekstrakta.
6-(4-cyclohexylphenoxy)pyridin-3-amine of formula IIIc, or one of its salts, solvates, tautomers, or stereoisomers thereof. 
-(4-cikloheksilfenoksi)piridin-3-amin formule IIIc, [image] Ili jedna od njegovih soli, otopina, tautomera ili stereoizomera istog.
Process according to claims 1 and 5, wherein the oxazolone of formula (3) is obtained from (16) and immediately reacted, without isolation and purification, with intermediate (4) to give the final product ibodutant. 
Postupak prema patentnim zahtjevima 1 1 5, naznačen time da oksazolon formule (3), dobiven iz spoja (16), bez izolacije i pročišćavanja odmah reagira s međuproduktom (4) dajući konačni produkt ibodutant.
In general, the formulations comprise from 0.01 to 95% by weight, preferably 0.5 to 90% by weight, of the mixture according to the invention. 
Općenito, formulacije sadrže od 0.01 do 95% mase, poželjno 0.5 do 90% mase, smjese prema izumu.
Ra represents a hydrogen atom or a C1-C6 alkyl group; 
R* predstavlja atom vodika ili C;-C alkil grupu.
of lymphocytes by compounds of the invention: 
Broj objave europskog patenta:
More preferably, the enteric coating polymer is selected from a copolymer of methacrylic acid and methyl methacrylate, and a copolymer of methacrylic acid and ethyl acrylate. 
Povoljnije, polimer enteričke obloge je izabran između kopolimera metakrilne kiseline i metil metakrilata i kopolimera metakrilne kiseline 1 etil akrilata.
In place of step 7D, the following procedure was employed: 
Umjesto faze 7D, korišten je sljedeći postupak:
cooling an aqueous solution containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide and meglumine to produce an amorphous frozen product of a meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; 
hlađenja vodene otopine koja sadrži 6-fluoro-3-hidroksi-2-pirazinkarboxamida i meglumin kako bi se proizveo amorfni zamrznuti produkt megluminske soli 6-fluoro-3- h id rosk i-2-p i razi nkarboksam ida;
The fuel pump nozzle as claimed in claim 3, wherein the hold-open latch member is designed as a pivotable lever (10). 
Pištolj za istakanje goriva bilo prema zahtjevu 3 ili zahtjevu 4, naznačen time da je element za blokiranje izveden kao jedna okretna polugica (10).
Caramel is manufactured by heating carbohydrates either alone or in the presence of food-grade acids, bases, and/or salts. 
Karamela se proizvodi zagrijavanjem ugljikohidrata bilo samih ili u prisutnosti prehrambenih kiselina, baza, i/ili soli.
A compound of general Formula (Ia) for use in the treatment and/or prevention of mycobacterial infections caused by nontuberculous mycobacteria (NTM), Mycobacterium leprae and multi drug resistant Mycobacterium tuberculosis wherein R1, R2 and R3 are each independently of one another, hydrogen, (C1-C4)alkyl, hydroxyl, halogen, methoxy or methoxy-acetic acid; 
Spoj opće formule (Ia) za uporabu u liječenju i/ili prevenciji mikobakterijskih infekcija uzrokovanih, netuberkuloznim mikobakterijama (NTM), Mycobacterium leprae, i multirezistentnom Mycobacterium tuberculosis, naznačeno time da
The method according to claim 13 or 14, wherein the component to be replaced is an object made from a ferritic-austenitic steel alloy having an elementary composition as defined in any one of the claims 1, 4, or 5, and subjected to a processing technique selected from the group consisting of machining, drilling and combinations thereof. 
Metoda prema zahtjevu 13 ili 14, pri čemu komponenta koja se zamjenjuje dolazi kao predmet dobiven iz feritno-austenitne čelične legure s elementarnim sastavom definiranim u zahtjevu 1, 4 ili 5 1 podvrgnut strojnoj obradi ili bušenju ili kombinaciji ove dvije tehnike.
The process according to claim 1, wherein the spherical polymer particles have a particle size distribution from 0.5 to 2.0. 
Postupak prema barem jednom od zahtjeva 1 do 7, naznačen time što polimerne čestice imaju raspodjelu veličine čestica u rasponu od 0.5 do 2.0.
an azetidine ring, (2) a pyrrolidine ring or (3) a piperidine ring optionally further substituted by 1 or 2 substituents selected from a halogen atom and a C1-6 alkyl group, or a salt thereof. 
azetidin-prsten, (2) pirolidin-prsten ili (3) piperidin-prsten prema potrebi dodatno supstituiran s jednim ili dva supstituenta odabrana od halogen atoma i -6 alkil-skupine, ili njegova sol.
In contrast to the varying turbidity and precipitation, bioactivity (IU) was essentially constant for the seven samples (around 19 IU/mg). 
Za razliku od varirajuće zamućenosti i taloženja, bioaktivnost (IU) je bila u biti konstantna za sedam uzoraka (oko 19 TU/mg).
The capsule of claim 12 wherein the binder is one of starch, cellulose, polyvinylpyrrolidone, xanthan gum, alginic acid, agar or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 14, naznačena time što se vezivo sastoji od škroba, celuloze, polivinilpirolidona, ksantan gume, alginske kiseline, agara ili kombinacija navedenog.
The energy savings system of claim 1, wherein the energy savings device is not configured to monitor characteristics of a load to which it is connected. 
Sustav za uštedu energije iz zahtjeva 1, gdje uređaj za uštedu energije nije izveden tako da nadzire karakteristike napona na koji je spojen.
• (c1) granulating a mixture of one or more excipient(s), a portion of the irbesartan and the wetting liquid to obtain granulate, and (c2) adding the remaining irbesartan and optionally further excipient(s) to the granulate to obtain a compression mixture; and compressing the compression mixture to the desired form. 
* (62) dodavanjem preostalog irbesartan hidroklorida i po izboru daljnjih pomoćnih tvari u granulat da bi se dobila smjesa za komprimiranje; te (ili) komprimiranje smjese za komprimiranje u željeni oblik. 8.
Iodobenzene diacetate is advantageously used in an amount of 0.99 to 1.85 mol, more advantageously 1.28 to 1.56 mol, per 1 mol of 7-ethyl-1,2,6,7-tetrahydrocamptothecin. 
Jodobenzen-diacetat se pogodno upotrebljava u količini od 0,99 do 1,85 mol, pogodnije 1,28 do 1,56 mol, na 1 mol 7-etil-1,2,6,7-tetrahidrokamptotecina.
a first pump (2) to compress the LNG and to communicate the compressed LNG downstream along the fuel gas supply line, 
prvu crpku (2) konfiguriranu da stlačuje LNG iz spremnika LNG (1), te da dobavlja komprimirani LNG prema drugoj crpki (4);
The protective wrapping according to claim 1, wherein the outward facing edge of the foamed plastic strips has a wavelike profile to prevent bulking of the foamed plastic strips when the protective wrapping is wrapped around the edges of the cylindrical object. 
Zaštitni omotač (200) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prema van okrenuti rub pjenastih plastičnih vrpci ima valoviti profil (208a, 208b) kako bi se sprječilo nabreknuće pjenastih plastičnih vrpci kada je zaštitni omotač namotan oko rubova valjkastog objekta.
In addition, changing the solid support after each protein production phase is time-consuming. 
Dopunski, mijenjanje krutih potpora nakon svake faze u proizvodnji proteina oduzima vremena.
A method for generating and maintaining a magnetic field with a field reversed configuration (FRC) within a confinement chamber of a system comprising: 
Postupak generiranja i održavanja magnetnog polja obrtne konfiguracije (FRC) unutar zaporne komore (100) jednog sustava, naznačen time, da taj sustav obuhvaća sljedeće:
Taurocholic acid and lecithin is added to a concentration of 3 mmol/l and 0.75 mmol/l respectively. 
Dodani su tauroklorna kiselina i lecitin u koncentraciji do 3 mmol/l odnosno 0.75 mmol/.
The compound or salt of claim 1 or 2, wherein R1 is methyl, ethyl, isopropyl, or tert-butyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je R1 metil, etil, izopropil ili tert-butil.
The total sum of investments in such automated packing machinery is huge and the total number of packaging, produced in the CD- and DVD-industries, exceeds 5 billion pieces per year. 
Ukupan iznos investicija u takve automatizirane strojeve za pakiranje je ogroman i ukupan broj pakiranja koja se proizvode u industrijama CD-a i DVD-a prelazi 5 milijardi komada po godini.
M is an alkali metal ion, alkaline earth metal ion, ammonium ion, organic ammonium ion and/or H; a is 1 or in the case of alkaline earth metal ions is 1/2. 
M je ion alkalnog metala, ion zemnoalkalnog metala, amonijak ion, organski amonijak ion i/ili H, a je 1 ili u slučaju iona zemnoalkalnih metala 1/2.
The composition of claim 8, which further comprises an agent selected from B2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, and combinations thereof; wherein the crystalline form and the agent are formulated together or separately. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time, da nadalje sadržava agense odabrane od agonista (3, adrenergičkih receptora, steroidnih protuupalnih agensa, inhibitora fosfodiesteraze-4 i njihovih kombinacija; pri čemu su kristalni oblik i agens formulirani zajedno ili odvojeno.
A saccharide of the formula: wherein T is of the formula (A) or (B): n is an integer from 1 to 100; 
OH O P=0 naznačen time što T ima formulu (A) ili (B):
It will be appreciated that when the compounds of the present invention are administered in combination with other therapeutic agents normally administered by the inhaled or intranasal route, that the resultant pharmaceutical composition may be administered by the inhaled or intranasal route. 
Treba imati na umu da kada se spojeve prema ovom izumu primjenjuje u kombinaciji s drugim terapijskim sredstvima, koja se inače primjenjuje inhalacijski ili intranazalno, da se i konačni farmaceutski pripravak može primijeniti inhalacijom ili intranazalno.
Such lozenges may also be subject to variable or over-rapid drug release as they have a mouth feel which is likely to prompt chewing or sucking rather than parking the lozenge and allowing it to dissolve. 
Takve pastile mogu također biti podvrgnute promjenljivom ili prebrzom oslobađanju lijeka jer one imaju takav ukus u ustima koji će vjerovatno potaći Zvakanje ili sisanje prije nego stajanje pastile i omogućavanje da se ona otopi.
at least one NMDA-antagonist selected from the group consisting of (R,S)-ketamine or an acid addition salt thereof such as the hydrochloride addition salt, (S)-ketamine or an acid addition salt thereof such as the hydrochloride addition salt, and memantine or an acid addition salt thereof such as the hydrochloride addition salt thereof. 
barem jedan antagonist NMDA odabran iz skupine koju čine (R,S)-ketamin ili njihova kisela adicijska sol, kao što je hidrokloridna adicijska sol, (S)-ketamin ili njihova kisela adicijska sol, kao što je hidrokloridna adicijska sol, te memantin ili njegova kisela adicijska sol, kao što je njegova hidrokloridna adicijska sol.
1 . The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in about 75 wt. % to about 99.99 wt. %. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u od 75% do 99,99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and 
Ry je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heleroarilalkila, i (NRcRp)sulfonila; a
A compound having the formula wherein R1 and R2 are independently halogen, unsubstituted aryl, unsubstituted heteroaryl, or a substituted aryl or heteroaryl group; 
Spoj koji ima formulu naznačen time da su R; i R>neovisno halogen, nesupstituirani aril, nesupstituirani heteroaril, ili supstituirana aril ili heteroaril skupina; 15
washing the reaction mixture with an aqueous solution; and 
(c) ispiranje reakcijske smjese vodenom otopinom; i
The method according to claim 1, wherein the side of said band (W) of flexible laminated material opposite the heat-sealing side is pre-printed, said edges (L 1, L 2) being overlaid in such a manner that the respective printed parts are perfectly aligned, said trimming determining a perfect continuity in the printing provided on said edges (L 1, L 2). 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je stranica navedenog pojasa (W) fleksibilnog laminiranog materijala nasuprot toplinski ljepljive stranice predotisnuta, navedeni rubovi (L1, L2) su prekriveni na takav način da su navedeni predotisnuti dijelovi savršeno poravnati, navedeno rezanje određuje savršeni kontinuitet u otiskivanju koje se nalazi na navedenim rubovima (L1, L2).
The apparatus according to claim 1, wherein: the windscreen anchor device is mounted in a fixed longitudinal position on the support arm. 
uređaj za sidrenje vjetrobranskog stakla sadrži usisnu napravu (14); i / ili pri čemu je uređaj za sidrenje vjetrobranskog stakla (14) montiran u fiksnom uzdužnom položaju na izduženoj potpornoj ruci (16).
or 10 membered bicyclic heteroaryl, having 1, 2 or 3 heteroatoms independently selected from the group of O, N and S(O)r, wherein r is 0, 1 or 2; wherein each of said groups a), b) and c) is optionally substituted with 1 or more substituents independently selected from the group of C1-4-alkyl-, C1-4-alkyl-O-, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, C3-6-cycloalkyl- and C3-6-cycloalkyl-O- and in case a substituent is attached to a nitrogen ring atom said substituent is selected from the group of C1-4-alkyl-, C1-4-alkyl-CO-, C3-6-cycloalkyl- and C3-6-cycloalkyl-CO-, 
dok je svaka od navedenih skupina a), b) i c), opcijski supstituirana s jednim ili više supstituenata neovisno odabranih iz skupine koju čine: C1-4-alkil-, C1-4-alkil-O-, oksetanil, tetrahidrofuranil, tetrahidropiranil, C3-6-cikloalkil- i C3-6-cikloalkil-O- te u slučaju da je supstituent priključen na dušikov atom u prstenu, tada je navedeni supstituent odabran iz skupine koju čine: C1-4-alkil-, C1-4-alkil-CO-, C3-6-cikloalkil- i C3-6-cikloalkil-CO-, i gdje svaki od navedenih supstituenata: C1-4-alkil-, C1-4-alkil-O-, C1-4-alkil-CO-, oksetanil, tetrahidrofuranil, tetrahidropiranil, C3-6-cikloalkil-, C3-6-cikloalkil-CO- ili
a cholestanol derivative represented by formula (1): (wherein G is GlcNAc-Gal- or GlcNAc-) or a cyclodextrin inclusion compound thereof, and 
1. Protutumorsko kemoterapijsko sredstvo, naznačeno time, da sadrži u kombinaciji, (a) derivat kolestanola predstavljenog formulom (1):
Also this allows time for manipulating the outlet end of the container if this should be necessary, e.g. 
Time je također omogućeno i vrijeme potrebno za rukovanje s izlaznim krajem spremnika ako bi to bilo potrebno, npr.
Preparation of 2,3-Dehydrotetrabenazine 
Priprema 2,3-dehidrotetrabenazina
The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 4, pri čemu navedeni fuzijski protein sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
Also, prior to loading, the column was equilibrated with buffer PBS pH 6.1, and after loading the first wash was carried out with the same buffer. 
Isto tako je prije nanošenja kolona ekvilibrirana sa PBS- puferom pH 6.1 i nakon nanošenja provedeno je prvo ispiranje sa istim puferom.
The compound according to item 1 wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
Ri, R2, 1 Ra su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARsg i (NRaARs)karbonila; Aje
According to another beneficial embodiment of the invention, the base is fixed to the airfoil surface by double-sided adhesive tape with a thickness of at least 0.3%, for example at least 0.5% and for example about 1% of the largest length in solid baseplate material. 
Lopatica vjetroturbine prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je navedena baza pričvršćena za površinu zračne folije dvostranom ljepljivom trakom (11, 12, 13) debljine najmanje 0.3%, na primjer najmanje 0.5% i na primjer oko 1% najveće dužine u osnovnoj podlozi čvrstog materijala.
Typically said respiratory disease is asthma, acute or chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), bronchial hyperreactivity or rhinitis, in particular asthma or chronic obstructive pulmonary disease (COPD). 
U tipičnom je slučaju navedena respiratorna bolest astma, akutni ili kronični bronhitis, emfizem, kronična opstruktivna plućna bolest (KOPD), bronhalna hiperreaktivnost ili rinitis, a osobito astma ili kronična opstruktivna plućna bolest (KOPD).
A process according to feature 7, wherein the step (f) comprises crystallisation using a toluene and isohexane solvent system. 
Postupak prema zahtjevu 7, naznačen time da korak (1) sadrži kristalizaciju uz korištenje sustava otapala toluena i izoheksana. nN=0
A process according to any of claims 1 to 6, wherein the process comprises; subjecting at least one solid material to mechanical micronization, milling, jet milling, grinding or mixtures thereof; and 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu postupak obuhvaća: a) podvrgavanje barem jednog čvrstog materijala mehaničkoj mikronizaciji, mljevenju, mlaznom mljevenju, drobljenju ili njihovim kombinacijama; i b) primjenu ultrazvuka na čvrsti materijal iz koraka (a).
A process for synthesizing 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)pyridazine, where the process comprises reacting 3-chloro-6-(4-cyclopropyl-piperazin-1-yl)pyridazine with 3,4-methylene-dioxybenzene boronic acid. 
Spoj, naznačen time, da je to 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin ili njegova farmaceutski prihvatljiva sol ili solvat. Spoj prema zahtjevu 1, naznačen time, da solvat je hidrat.
Ophthalmic preparation in the form of eyedrops comprising BDNF in a concentration of at least 15 µg/µl for use in the prevention and/or treatment of neurodegenerative diseases of the retina, optic nerve and lateral geniculate body. 
Oftalmološki pripravak u obliku očnih kapi, naznačen time da sadrži BDNF u koncentraciji od najmanje 15 ug/uI, za primjenu u sprječavanju i/ili liječenju neurodegenerativnih bolesti retine, optičkog živca 1 lateralne genikulatne jezgre.
The cells are harvested 72 h post infection and membranes prepared. 
Žetva stanica se vrši 72 sata nakon infekcije i membrane su na taj način pripravljene.